Uncategorized
EyeGate reports $2.9 million quarterly loss
EyeGate Pharmaceuticals reported a net loss of $2.9 million in the first quarter of 2017 compared with a net loss of $2.4 million in the same quarter of 2016. Revenue was $0.19 million for the quarter, and research and development costs were $1.8 million compared with no revenue in 2016’s first quarter and research and development costs of $0.9 million, according to a company press release.